Circulating cell-free DNA (ccfDNA), refers to degraded DNA fragments that circulate freely in body fluids such as blood plasma, urine, and cerebrospinal fluid. These fragments vary in size, reflecting ...

More information: Mohamed Adil et al, Preeclampsia risk prediction from prenatal cell-free DNA screening, Nature Medicine (2025). DOI: 10.1038/s41591-025-03509-w ...

A cell-free DNA (cfDNA) blood test, aimed at detecting abnormal DNA signals in people with an average risk of colorectal cancer (CRC), correctly detected CRC in most people confirmed to have the ...

Liquid biopsy techniques using cell-free DNA (cfDNA) play an increasingly important role in the characterization and surveillance of solid tumors. For blood cancers, molecular response assessment ...

The usefulness of the cell-free DNA blood test (cf-bDNA) can vary based on the reasons for using the method of screening for colorectal cancer (CRC). According to a new study published in Annals ...

A blood-based cell-free DNA (cfDNA) test was able to find patients at increased risk of colorectal cancer (CRC), advanced neoplasia, and advanced precancerous lesions among those who were at ...

In a comparison against multiple alternative screening strategies, a cell-free DNA blood test (cf-bDNA) prevented the fewest cancers and cancer-specific deaths versus no screening. With an ...

Cell-free DNA testing uses a small amount of a person's blood and tests it for a large number of cancers. A positive test could indicate that the person has a certain type of cancer in theory ...

The Food and Drug Administration (FDA) has approved Guardant Health’s Shield ™ blood test for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older ...